Figure 4.
MAb131 demonstrates in vivo activity against primary AML. (A) Immunodeficient (NSG) mice were injected with 1 × 106 EPHB4+ primary AML cells (AML18) to create orthotopic xenografts. AML18 was characterized by normal cytogenetics, CEBPA mutant, and NPM1 mutation; 5 to 6 NSG mice per treatment group. Two weeks after injection, treatment mice were treated with PBS (untreated), AraC (50 mg/kg IP weekly), MAb131 10 mg/kg 3 times per week, or the combination. Treatments continued until all control mice were killed for evidence of disease. Remaining mice were observed for survival. Engraftment was confirmed at necropsy. (B) The table predicts median survival, range, and adjusted P values, after Bonferroni correction, for each survival curve.
